Abstract: Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.

Abstract: A novel process for racemization of (S)-3-carbamoylmethyl-5-methyl-hexanoic acid to 3-carbamoylmethyl-5-methyl-hexanoic acid racemate has been developed.

Abstract: Subject of the invention is a method for the production of L-carnitine, comprising the steps of (a) providing a solution comprising at least 5% (w/w) carnitine in a first solvent, wherein the carnitine is a mixture of D- and L-carnitine, (b) optionally seeding the solution with L-carnitine crystals, (c) adding an second solvent, in which the L-carnitine is not soluble or has a low solubility, (d) isolating crystals comprising L-carnitine.

Abstract: The present invention relates to a process for resolving S-3-(Aminomethyl)-5-methylhexanoic acid, which adopts benzoyl-L-glutamic acid, 4-methyl benzoyl-L-glutamic acid, benzene sulfonyl-L-glutamic acid or 4-methyl benzene sulfonyl-L-glutamic acid as a resolution agent to make a first resolution to racemic 3-aminomethyl-5-methylhexanoic acid, and adopts the resolution agent same to that of the first resolution to make a second resolution to the first resolution product to obtain the second resolution product, thus the resolution salt product is obtained, and further hydrolyzed by an acid, the resolution agent is extracted to be separated, the pH is adjusted to be neutral, the product S-3-(Aminomethyl)-5-methylhexanoic acid, i.e.

Abstract: This invention provides a process of making optically pure melphalan of the formula by hydroxyethylation, in a regioselective manner, of the aromatic amino group rather than the glycinic amino group.

Abstract: Methods for producing compounds having activity as an ?2? ligand are provided.

Abstract: According to the present invention, crystals comprising (2R)-2-propyloctanoic acid and an amine, which can be used as bulk drugs for safely orally administrable solid preparations with keeping the pharmacological effect, are provided. Among these crystals, the crystal with dibenzylamine per se is particularly useful as bulk drug for pharmaceuticals and can be used as an intermediate to produce (2R)-2-propyloctanoic acid having an optical purity of more than 99.5% e.e. which has not been obtained.

Abstract: The present invention relates to a novel process for the preparation of ?-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid 1, which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid 2.

Abstract: The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to a novel intermediate useful in the preparation of ambrisentan and a process for the preparation of the intermediate. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a polymorphic form, designated as Form I of ambrisentan and a process for the preparation of the Form I.

Abstract: Described herein are composite materials and methods of using them for the separation or purification of enantiomers. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through the support member; and a macroporous cross-linked gel, comprising a plurality of macropores, and a plurality of pendant chiral moieties. In certain embodiments, the composite materials may be used in the separation or purification of a chiral small molecule.

Abstract: This invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. This method significantly shortens the time taken for optical transformation, and enables the repeated use of an organic solution containing a enantioselective receptor, to thereby obtain optically pure amino acids in a simple and remarkably efficient manner, and to enable the very economical mass production of optically pure amino acids.

Abstract: High yields and purity are obtained in the purification of enantiomers of chiral carboxylic acids by preparative-scale chromatography by including a tertiary alcohol in the mobile phase in conjunction with an acidic modifier and a hydrophobic solvent. The tertiary alcohol is superior to other, more commonly used alcohols by reducing the extent of esterification of the enantiomer that otherwise lowers the yield and the purity.

Abstract: The present invention relates to a medicament which is useful for neurodegenerative diseases, which comprises about 1 to about 5 equivalents of a basic metal ion based on 1 equivalent of (2R)-2-propyloctanoic acid or a salt thereof, which is supplied from a metal salt of weak acid or a metal hydroxide, and optionally further comprises an additive. The medicament of the present invention is a medicament which a pH of suitable for intravenous administration, is resistant to fluctuations of the pH and is not clouded when it is dissolved in an infusion, and an injection and the like can be prepared therefrom by using any dissolving liquid and/or dilution liquid.

Abstract: The present invention is a simple method, in which a specific amount of alkali is added to an enantiomeric mixture of an optically active organic carboxylic acid where enantiomers are present in a non-equimolar ratio, or in which the enantiomeric mixture of an optically active organic carboxylic acid is neutralized with an alkali, and then a specific amount of acid is added thereto, thereby separating an organic carboxylic acid salt in the mother liquor and a crystallized organic carboxylic acid from each other. The method makes it possible to obtain an optically active organic carboxylic acid with improved enantiomeric excess. The present invention provides a simple production method for obtaining an optically active organic carboxylic acid with improved enantiomeric excess from an enantiomeric mixture of an optically active organic carboxylic acid where enantiomers are present in a non-equimolar ratio.

Abstract: Processes for making a diester compound of formula (B) and for converting it to pregabalin, especially via a compound of formula (2), can provide several advantages. The compound (B) can be converted to the compound (2) via reductive hydrogenation.

Abstract: There is described a process for the manufacture of a racemic 2-aryl propionic acid compound, or a pharmaceutically acceptable salt thereof, which comprises reacting the S- or R-enantiomer of the corresponding 2-aryl propionic acid compound with a base.

Abstract: Disclosed herein is a process for the preparing (S)-3-(aminomethyl)-5-methylhexanoic acid by optical resolution of (±)-3-(aminomethyl)-5-methylhexanoic acid and a resolving agent employing a suitable solvent.

Abstract: The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

Abstract: The present invention relates to a novel process of preparing an enantiomerically enriched ?-amino acid, such as enantiomerically enriched (S)-pregabalin.

Abstract: The present invention relates to a process for resolving S-3-(Aminomethyl)-5-methylhexanoic acid, which adopts benzoyl-L-glutamic acid, 4-methyl benzoyl-L-glutamic acid, benzene sulfonyl-L-glutamic acid or 4-methyl benzene sulfonyl-L-glutamic acid as a resolution agent to make a first resolution to racemic 3-aminomethyl-5-methylhexanoic acid, and adopts the resolution agent same to that of the first resolution to make a second resolution to the first resolution product to obtain the second resolution product, thus the resolution salt product is obtained, and further hydrolyzed by an acid, the resolution agent is extracted to be separated, the pH is adjusted to be neutral, the product S-3-(Aminomethyl)-5-methylhexanoic acid, i.e.

Abstract: The present invention relates to a preparation method of carboxylic acids with optical activity, particularly, publishes that very useful chiral carboxylic acids can be obtained by the asymmetric catalytic hydrogenation of tri-substituted ?,?-unsaturated carboxylic acids, with the complexes of the chiral phosphor nitrogen ligands and iridium used as the catalysts which show high activity and enantioselectivity (up to 99.8% ee), thus provides a more efficient method with higher enantioselectivity for asymmetric catalytic hydrogenation of chiral carboxylic acid-like compounds, and has important application value to asymmetric hydrogenation of chiral carboxylic acids.

Abstract: The present invention relates to a novel method for the preparation of racemic pregabalin (1) or a single enantiomer thereof, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2).

Abstract: The present invention provides a process for resolving racemic pregabalin to S-pregabalin by using a chiral acid to form a pregabalin salt, purifying the salt to obtain a purified S- pregabalin salt then neutralizing the salt to obtain S-pregabalin having good chiral purity.

Abstract: A process for the recovery of substituted tartaric acid resolving agents from resolution process liquors comprising organic solvents, wherein the substituted tartaric acid derivatives are neutralised by adding a base, extracted into an aqueous phase and crystallized from the aqueous phase by addition of a mineral acid in the presence of an organic solvent.

Abstract: Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal raw drug but also use of the crystals as an intermediate can yield (2R)-2-propyloctoic acid having an optical purity exceeding 99.5% e.e., which has not been obtained hitherto.

Abstract: The present invention is concerned with the resolution of a mixture of enantiomers of N-protected amino acids by crystallization with enantiomerically pure N-unprotected ?-amino acid derivatives.

Abstract: A method of efficiently extracting a high-purity stereoisomer from a mixture comprising the endo isomer and the exo isomer of a dicarboxylic acid having a norbornene or norbornane structure, or a derivative thereof. The present invention relates to a method of separating the endo isomer and the exo isomer of a dicarboxylic acid represented by a general formula (1) or (2) or a derivative thereof, and includes the step of stirring and mixing a mixture comprising mainly the endo isomer of the dicarboxylic acid represented by the general formula (1) or (2) or a derivative thereof, and the exo isomer of the dicarboxylic acid represented by the general formula (1) or (2) or a derivative thereof, with a basic compound and a solvent. (wherein, R1 to R8 represent a hydrogen atom, methyl group, ethyl group, or butyl group), (wherein, R?1 to R?10 represent a hydrogen atom, methyl group, ethyl group, or butyl group).

Abstract: The invention relates to pure (R)-CMH and to the optical resolution of CMH-racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)-CMH and to the process for isolating (S)-CMH from the mother liquor.

Abstract: The present invention discloses an ibuprofen amine salt and the synthesis thereof, and more particularly an ibuprofen amine salt yielded by the neutralization reaction of a racemic mixture of ibuprofen with tris(hydroxymethyl)aminomethane in a solution system of water and an organic solvent. Compared with racemic mixtures of ibuprofen, the ibuprofen amine salt has higher solubility and a higher melting point, thereby having better bioavailability and properties than racemic mixtures of ibuprofen during pharmaceutical processing. Further, the ibuprofen amine salts of the present invention are stable between pH 4 and 9 so that they can be more widely applied to medicines.

Abstract: The present invention relates to a reagent for determining the absolute configuration of a chiral compound containing as an active ingredient a metalloporphyrin dimer, wherein the metalloporphyrin dimer has an alkaline-earth metal ion as a central metal and has a carbon chain-crosslinked structure in which at least one of the two porphyrin rings has a substituent bulkier than methyl at least one of the second carbon atoms from a carbon atom bonded to the crosslinking carbon chain along the outer periphery of the porphyrin ring and a method for determining the absolute configuration of an asymmetric carbon atom of the chiral compound using the reagent.

Abstract: The invention relates to pure (R)—CMH and to the optical resolution of CMH-racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)—CMH and to the process for isolating (S)—CMH from the mother liquor.

Abstract: The present invention relates to novel chiral resolving agents and a process for resolution of racemic organic acids and their derivatives of the formula (+, ?)—R1R2CHCOOR3 with Cis-(1S,4S)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Cis-(1R,4R)-isomer as well as Trans-(1S,4R)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Trans-(1R,4S)-isomer.

Abstract: The invention provides a process for producing optically active 2,2-dimethylcyclopropanecarboxylic acid by reacting an optical isomer mixture of 2,2-dimethylcyclopropanecarboxylic acid with an optically inactive amine to form (precipitate, crystallize or the like) an ammonium salt of optically active 2,2-dimethylcyclopropanecarboxylic acid, for example, optically active (S)-(+)-2,2-dimethylcyclopropanecarboxylic acid. The production (optical resolution, separation of an optically active substance, purification of an optically active substance or the like) of optically active 2,2-dimethylcyclopropanecarboxylic acid which is important as an intermediate for production of agricultural chemicals, medications and the like can easily be conducted at low cost.

Abstract: The present invention provides a methods and compounds for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

Abstract: Disclosed is an alanine racemase chiral binaphthol derivative having the ability to recognize amino alcohols selectively on the basis of chirality and transform amino acids from an L-form into a D-form. Methods for the optical resolution of amino acid or amino alcohol and for the optical transformation of D- and L-forms of amino acids using the binaphthol derivative are also provided.

Abstract: High yields and purity are obtained in the purification of enantiomers of chiral carboxylic acids by preparative-scale chromatography by including a tertiary alcohol in the mobile phase in conjunction with an acidic modifier and a hydrophobic solvent. The tertiary alcohol is superior to other, more commonly used alcohols by reducing the extent of esterification of the enantiomer that otherwise lowers the yield and the purity.

Abstract: The present invention provides a methods and compounds for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

Abstract: The present invention provides a process for the preparation of substantially racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.

Abstract: Crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.8, 18.4, 19.2, 20.7, and 23.7° 2?±0.2° 2?, methods for its preparation, its pharmaceutical compositions thereof, and methods for the preparation of crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.7, 15.4, 17.2, 18.2, and 23.0° 2?±0.2° 2?, are provided.

Abstract: A process is described to prepare a single enantiomer of an amino acid from its opposite enantiomer or from a racemic mixture, using an oxidase biocatalyst and a supported metal catalyst in separate, sequential reactions in water. The process can be operated in batch or continuous mode.

Abstract: Provided is a dynamic resolution method of enriching a desired isomer of an alpha-substituted carboxylic acid relative to an undesired isomer, the method comprising: (a) in a solvent, contacting the alpha-substituted carboxylic acid, wherein the alpha substitution is with a leaving group and wherein the alpha carbon is chiral, with a homochiral amine to form a salt that is partially insoluble under selected reaction conditions, wherein the homochiral amine is selected so that the solubility of the amine salt of the undesired alpha-substituted carboxylic acid is greater than that of the amine salt of the desired alpha-substituted carboxylic acid under the selected reaction conditions; (b) reacting under the selected reaction conditions the salt with a nucleophile, wherein the reacting is effective in producing a net increase in the less soluble amine salt of the alpha-substituted carboxylic acid, and wherein the selected conditions are selected to (i) promote nucleophilic substitution of the nucleophile and th

Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.

Abstract: Optically active ?-phenylalanine compound may be prepared in an industrially advantageous manner by reacting an N-acyl-?-phenylalanine compound with a specific optically resolving agent to effect an optical resolution by formation of diastereomer salts, and removing the optically resolving agent from each diastereomer, to give an optically N-acyl-?-phenylalanine compound. Deacylation may be further carried out to obtain an optically active ?-phenylalanine compound.

Abstract: The subject of the present invention is the preparation of the (R)-(?)-2-hydroxy-2-(2-chlorophenyl)acetic acid of the formula (I) by the resolution of the corresponding racemic compound by using the compounds of the general formula (II).

Abstract: Optically active diphenylalanine compounds may be conveniently prepared in a good yield by reacting a diphenylalanine compound represented by formula (1) with an optically active amine compound represented by formula (2) in the presence of an organic solvent to give a diastereomeric salt represented by formula (5) and then treating the diastereomeric salt under acidic conditions to give an optically active diphenylalanine compound represented by formula (3): wherein each symbol is as defined in the specification.

Abstract: A process for preparing an optically active biaryl compound the formula (4): which comprises reacting an aromatic sulfonic acid ester compound of the formula (1): with an organic boron compound of the formula (2): at 70° C. or below in the presence of a nickel catalyst and a base. The biaryl compounds produced using this process possess a high optical purity and are useful as intermediates for medicaments, agrochemicals, etc.

Abstract: Provided is a separating method for an optical isomer mixture comprising the steps of mixing an amino acid derivative such as N-(tert-butoxycarbonyl)-DL-alanine in which optical isomers of a D type and an L type are present in a mixture with a hydrophilic compound such as ?-cyclodextrin having a different affinity to two kinds of the optical isomers described above and then bringing the resulting aqueous solution or aqueous suspension into contact with a hydrophobic substance such as a solid matter subjected on a surface thereof to hydrophobic treatment on the condition that the pH is 3.5 or lower or under the coexistence of ions including an atomic group having hydrophobicity which can be a counter ion for the amino acid derivative described above such as a triethylammonium ion to thereby separate the D type amino acid derivative from the L type amino acid derivative present in the above aqueous solution or aqueous suspension.

Abstract: The process for separating the R(?)- and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-sulfonamide enantiomers comprises (a) reacting a mixture of said enantiomers with an optically active organic acid to form diastereoisomeric salts with said enantiomers, where in said diastereoisomeric salts have different solubility and can be separated by crystallization; (b) separating the diastereoisomeric salt mixture enriched in the salt of one of the enantiomers; and (c) releasing said salts to obtain the R(?)or S(+) enantiomer. The R(?)-5-[2-[[2-(2-ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide enantiomer has ?-adrenergic blocking activity and is useful as an antihypertensive agent suitable for the treatment of congestive heart failure and benign prostatic hypertrophy.

Abstract: This invention is drawn to a process for the production of (R,R)-phenylisoserine or a 1–4C-alkyl ester thereof.

Abstract: The present invention relates to: a method for producing ?-hydroxycarboxylic acid, which comprises hydrolyzing cyanohydrin in the presence of a hydrocarbon solvent; a method for producing optically active ?-hydroxycarboxylic acid, which comprises: producing optically active cyanohydrin by performing a reaction between a carbonyl compound and hydrogen cyanide, using a solvent comprising at least one organic solvent selected from a group consisting of an alcoholic solvent, an ester solvent, an ethereal solvent and a carboxylic solvent; removing said organic solvent from said reaction solvent; and hydrolyzing the remaining reaction mixture without isolating optically active cyanohydrin; a method for producing optically active ?-hydroxycarboxylic acid, which comprises hydrolyzing optically active cyanohydrin, using at most 10 equivalents of mineral acid relative to said optically active cyanohydrin under the condition that maximum temperature when reacting is 90° C.